key: cord-1007089-dybozins
authors: Berkowitz, Kathleen M.; Goje, Oluwatosin; Eaton, Jennifer
title: IMPLEMENTATION OF UNIVERSAL TESTING FOR SARS-CoV-2 IN PREGNANT WOMEN WITH INTENDED ADMISSION FOR DELIVERY
date: 2020-07-11
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2020.07.011
sha: b79d23df9c026fe5bbda8541f2ed65beba62b432
doc_id: 1007089
cord_uid: dybozins

nan

Cleveland Clinic Foundation recently implemented a policy OF SARS-CoV-2 testing for all 9 pregnant patients with planned delivery or admitted for labor at obstetric units in Ohio. We 10 present our experience with the feasibility of testing, issues of patient autonomy and prevalence 11 rates. In contrast to a recent report (1) on universal screening of pregnant women residing in an 12 area of high disease prevalence, our experience derives from a population experiencing a low 13 prevalence of active disease.

14 Patients with planned delivery were tested 3-5 days prior to admission using a CDC approved 15 RT-PCR testing platform. Pre-admission testing was available at two sites. Patients presenting 16 in spontaneous labor were tested using a rapid platform (Xpert Xpress SARS-CoV-2 (Cepheid,

Sunnyvale CA)). Testing was "opt-in". Patients who declined pre-admission testing were 18 offered a rapid test at the time of admission.

From 5/1/15 to 5/15/2020, 518 women were admitted for delivery. All 518 had orders for testing 

Screening all pregnant women admitted to 40 labor and delivery for the virus responsible for coronavirus disease 2019

SARS-CoV-2 in pregnancy: symptomatic women are 43 only the tip of the iceberg

Universal Screening for SARS-CoV-2 in 46

Women Admitted for Delivery